Mikrognathia dan Makrognathia

01Pathophysiology

Micrognathia

The mandible develops from the first pharyngeal arch (also called the mandibular arch), which is populated by neural crest cells that migrate into the arch mesenchyme during the fourth to fifth week of embryonic development. These cells differentiate around Meckel's cartilage, the cartilaginous template that guides mandibular ossification through intramembranous bone formation. Any disruption in neural crest cell migration, proliferation, or differentiation leads to mandibular hypoplasia.

In Pierre Robin sequence, the primary defect is believed to be early mandibular hypoplasia occurring before the 9th week of gestation. Because the mandible is too small, the tongue cannot descend from between the palatal shelves. This mechanical obstruction prevents palatal shelf fusion, resulting in the classic triad: micrognathia, glossoptosis, and a U-shaped (not V-shaped) cleft palate. The U-shaped morphology is a distinguishing feature because it reflects a mechanical cause (tongue blocking fusion) rather than a primary palatine defect.

The clinical consequence is straightforward once you understand the anatomy. A small mandible means the tongue base sits posteriorly, falling into the hypopharynx by gravity. This produces upper airway obstruction that worsens in the supine position. Neonates are obligate nasal breathers, so any additional compromise to the oropharyngeal airway can be life-threatening. Feeding difficulty arises because coordinated sucking requires adequate mandibular structure and tongue mobility, both of which are impaired.

Micrognathia can be isolated or syndromic. When syndromic, the underlying mechanism varies by condition. In Treacher Collins syndrome (mandibulofacial dysostosis), mutations in TCOF1 disrupt ribosomal biogenesis in neural crest cells, causing apoptosis and deficient first and second arch development. In trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome), generalized developmental disruption includes craniofacial structures. In Stickler syndrome, collagen gene mutations (COL2A1, COL11A1) produce connective tissue abnormalities that include mandibular hypoplasia.

Macrognathia

Macrognathia, or pathologic mandibular enlargement, most commonly appears in clinical testing in the context of acromegaly. The underlying mechanism is a growth hormone (GH)-secreting pituitary adenoma. Excess GH stimulates hepatic production of insulin-like growth factor 1 (IGF-1), which drives periosteal new bone formation and soft tissue hypertrophy.

Unlike long bones, the mandible does not have a growth plate that fuses. It undergoes appositional bone growth at the condyles and along the periosteal surfaces throughout life. This is why excess GH in adulthood preferentially enlarges acral structures: the mandible, hands, feet, and brow ridges. The mandible grows forward and downward, producing prognathism and dental spacing (diastema). Soft tissue effects include macroglossia, thickened skin, and enlargement of internal organs (organomegaly).

In Paget disease of bone, the mechanism is entirely different. Disordered osteoclast-mediated bone resorption is followed by disorganized, excessive osteoblastic new bone formation. The resulting bone is structurally abnormal (woven rather than lamellar), expanded, and deformed. When the skull and mandible are involved, the jaw enlarges asymmetrically, and patients may report that their dentures no longer fit. The key biochemical marker is a markedly elevated serum alkaline phosphatase with normal calcium and phosphorus levels.

In Beckwith-Wiedemann syndrome (an overgrowth syndrome due to imprinting defects on chromosome 11p15), mandibular enlargement occurs as part of generalized somatic overgrowth alongside macrosomia, macroglossia, omphalocele, and neonatal hypoglycemia.

02Classification and Clinical Manifestation

Micrognathia: Classification by Severity and Association

Macrognathia: Classification by Etiology

03Diagnostic Workup

Diagnostic Reasoning

For micrognathia, the workup begins at the bedside. The diagnosis itself is clinical, recognized by a visibly recessed mandible and retrognathia profile. Once identified, the critical question is whether the airway is compromised. Pulse oximetry and observation during feeding are the immediate assessments. If the neonate shows desaturation, stridor, or obstructive episodes, polysomnography (sleep study) quantifies the severity and guides surgical decision-making.

The next step is determining whether the micrognathia is isolated or part of a syndrome. A thorough dysmorphology examination looks for associated anomalies: ear malformations (Treacher Collins, Goldenhar), eye findings (myopia and vitreous abnormalities in Stickler), cardiac defects, limb anomalies, and cleft palate. A karyotype or chromosomal microarray is ordered when multiple anomalies suggest an aneuploidy. Targeted gene panels are used when a recognized syndrome is suspected clinically.

Lateral cephalometric radiography provides a standardized 2D assessment of mandibular size and jaw relationships (SNB angle, mandibular plane angle). 3D CT is reserved for surgical planning, particularly when mandibular distraction osteogenesis is being considered, as it maps the inferior alveolar nerve, tooth buds, and bone stock.

For acromegaly, the screening test is a serum IGF-1 level, which reflects integrated GH secretion over 24 hours (unlike GH itself, which is pulsatile). An elevated IGF-1 for the patient's age and sex is the initial red flag. The confirmatory test is the oral glucose tolerance test (OGTT): the patient drinks 75 grams of glucose, and GH is measured at intervals. In healthy individuals, glucose suppresses GH below 1 ng/mL. In acromegaly, GH fails to suppress, which is diagnostic. After biochemical confirmation, pituitary MRI with gadolinium localizes the adenoma and determines whether it is a microadenoma (10 mm) or macroadenoma ($\ge \backslash geq$10 mm).

For Paget disease, a markedly elevated serum alkaline phosphatase with normal serum calcium and normal phosphorus is the hallmark laboratory pattern. Plain radiographs show characteristic changes: lytic lesions (early "osteolytic" phase), mixed lytic-sclerotic areas, and eventually dense sclerotic bone with cortical thickening. A technetium-99m bone scan identifies the full extent of skeletal involvement and is useful for staging.

04Management and Treatment

Micrognathia management is severity-driven. The first step in any neonate with micrognathia and airway compromise is prone positioning. This simple maneuver uses gravity to pull the tongue base forward, relieving the obstruction in the majority of mild cases. Feeding modifications (upright positioning, specialized nipples, nasogastric tube feeding if oral feeding fails) address the nutritional component.

If prone positioning is insufficient, the next step is a nasopharyngeal airway (NPA), a soft tube inserted through the nose past the tongue base into the hypopharynx. The NPA bypasses the glossoptosis and maintains a patent airway. This is often a bridge measure while awaiting further intervention.

For infants who remain obstructed despite conservative measures, mandibular distraction osteogenesis (MDO) is now the preferred surgical option. The procedure involves making a controlled osteotomy (bone cut) in the mandibular ramus bilaterally, placing distraction devices, and gradually lengthening the mandible at a rate of approximately 1 mm per day over 10 to 14 days. The distraction phase is followed by a consolidation phase of 6 to 8 weeks during which new bone fills the gap. MDO has largely replaced tracheostomy as the definitive airway intervention in neonatal micrognathia.

Tracheostomy remains an option for the most severe cases, infants with multilevel airway obstruction, or situations where MDO is not feasible. However, tracheostomy carries significant morbidity in neonates (accidental decannulation, granulation tissue, tracheal stenosis) and is therefore avoided when possible.

Cleft palate repair, if present in Pierre Robin sequence, is typically performed at 9 to 12 months of age following the standard cleft palate repair timeline.

For acromegaly, the first-line treatment is transsphenoidal surgery to remove the GH-secreting pituitary adenoma. Cure rates are highest for microadenomas (approximately 80-90%) and lower for macroadenomas, especially those with cavernous sinus invasion. Biochemical cure is defined as normalization of IGF-1 and GH suppression below 1 ng/mL on OGTT.

If surgery is not curative (residual disease, inoperable tumor), somatostatin analogs are first-line medical therapy. Octreotide LAR is given as 20 to 30 mg intramuscularly every 4 weeks. Lanreotide is given as 60 to 120 mg via deep subcutaneous injection every 4 weeks. These drugs suppress GH secretion by activating somatostatin receptors on the adenoma cells.

Pegvisomant is a GH receptor antagonist used for cases refractory to somatostatin analogs. It blocks GH action at the receptor level rather than suppressing secretion, so GH levels may actually rise while IGF-1 normalizes. The dose is 10 to 30 mg subcutaneously daily.

Cabergoline (a dopamine agonist) can be used as adjunctive therapy, particularly in tumors that co-secrete prolactin.

Radiation therapy (stereotactic radiosurgery or conventional fractionated radiation) is reserved as third-line treatment. Its onset of action is slow (years), and it carries a high risk of hypopituitarism.

Long-term management of acromegaly includes screening for comorbidities: cardiovascular disease (cardiomyopathy, hypertension), diabetes mellitus, obstructive sleep apnea, colon polyps (colonoscopy at diagnosis), and arthropathy.

05Differential Diagnosis and Distractors

Micrognathia Differentials

Macrognathia Differentials

06Traps and High-Yield Pearls

The most common testing error with micrognathia involves failing to recognize Pierre Robin sequence when the vignette describes a neonate with airway obstruction and feeding difficulty. Students often jump to primary airway diagnoses like laryngomalacia or choanal atresia without noting the small chin described in the physical exam. The vignette will embed the clue ("recessed mandible," "small jaw," or "retrognathic profile") within a longer description. If you see airway obstruction in a neonate combined with any mention of mandibular hypoplasia, Pierre Robin sequence should be at the top of your differential. Remember that the U-shaped cleft palate distinguishes Pierre Robin from an isolated cleft palate (which is V-shaped). Also, always recall that Pierre Robin is a "sequence" (one anomaly leading to a cascade), not a "syndrome" (multiple anomalies from a single cause). The initiating event is mandibular hypoplasia, and everything follows mechanically.

A second common trap is the management question. When a vignette describes a neonate with Pierre Robin and moderate obstruction, the answer is prone positioning as the first step, not intubation or tracheostomy. Students who pick an invasive intervention without attempting positional management first will lose the point. Only if prone positioning fails should you escalate to nasopharyngeal airway and then surgical intervention.

For macrognathia, the trap lies in recognizing acromegaly from subtle clues. The vignette may not say "jaw enlargement" directly. Instead, it will describe a patient whose rings no longer fit, whose shoe size has increased, who has new-onset carpal tunnel syndrome, or who has been told by a dentist about jaw spacing changes. The question is testing whether you connect peripheral findings to the central diagnosis of GH excess. Once you suspect acromegaly, the testing logic is always the same: screen with IGF-1, confirm with OGTT showing non-suppressible GH, and localize with pituitary MRI. Do not skip to MRI as the first step; this is a common sequencing error.

Finally, for Paget disease presenting with jaw enlargement, the pearl is the laboratory pattern: elevated alkaline phosphatase with normal calcium and normal phosphorus. If a vignette gives you a patient with an enlarging skull, hearing loss, and this lab pattern, Paget disease is the answer, and bisphosphonates are the treatment.